Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa

South African Medical Journal

Volumn 102, Issue 6, 2012, Pages 506-511

  Schutz, Charlotte ^a   Ismail, Zahiera ^b   Proxenos, Charles John ^b   Marais, Suzaan ^a   Burton, Rosie ^a   Kenyon, Chris ^a   Maartens, Gary ^a   Wilkinson, Robert J ^a,c,d   Meintjes, Graeme ^a,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GF Jooste Hospital   (South Africa)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; EFAVIRENZ; ETHAMBUTOL; GAMMA GLUTAMYLTRANSFERASE; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; OFLOXACIN; PROTEINASE INHIBITOR; RIFAMPICIN; STAVUDINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HOSPITAL; HOSPITAL PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRAHEPATIC CHOLESTASIS; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; RELAPSE; RETROSPECTIVE STUDY; SEPSIS; SOUTH AFRICA; TOXIC HEPATITIS; TUBERCULOSIS; BLOOD; HUMAN; KAPLAN MEIER METHOD; LENGTH OF STAY; LUNG TUBERCULOSIS; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ALANINE TRANSAMINASE; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; SOUTH AFRICA; TUBERCULOSIS, PULMONARY;

EID: 84865126338     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.5650     Document Type: Article

References (20)

1. UNAIDS. World Aids Day Report. Berlin/Geneva: UNAIDS, 2011. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf (accessed 3 January 2012).
2. Motsoaledi A. How we're re-engineering the health system. Johannesburg: Politicsweb, 2011. http://www.politicsweb.co.za/politicsweb/view/politicsweb/en/page71656?oid=238984&sn=Detail&pid=71616 (accessed 14 November 2011).
3. UNAIDS Republic of South Africa Country Progress Report on the Declaration of Commitment on HIV/AIDS. Berlin/Geneva: UNAIDS, 2010. http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/2010progressreportssubmittedbycountries/southafrica_2010_country_progress_report_en.pdf (accessed 14 November 2011).
4. WHO. Global Tuberculosis Control 2011. Geneva: WHO, 2011. http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf (accessed 14 November 2011).
5. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006;42(7):1040-1047.
6. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010;24(4):563-572.
7. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174(8):935-952.
8. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ.2004;170(2):229-238.
9. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167(11):1472-1477.
10. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202.
11. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354(7):731-739.
12. DAIDS. Table for Grading Adult and Pediatric Adverse Events. Version 1.0. 2004. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf (accessed 28 December 2011).
13. Department of Health (DoH). National Tuberculosis Management Guidelines 2008. Pretoria: DoH, 2008. http://www.sasohn.org.za/images/TBGUIDELINES2008SFINALFORPRINTINGMARCH09.pdf (accessed 28 December 2011).
14. Department of Health. National Antiretroviral Treatment Guidelines. Johannesburg: Jacana, 2004.
15. Nijland HM, L'Homme RF, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008;22(8):931-935.
16. Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS 2010;5(1):61-69.
17. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16(23):3041-3053.
18. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G. Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One 2009;4(2):e4520.
19. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007;21(10):1301-1308.
20. Pepper DJ, Marais S, Wilkinson RJ, et al. Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors. BMC Infect Dis 2010;10:83.